Citations

Clear

12 citation(s) found for "Sukumar, S".

Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update
Nahleh, Zeina , Alfano, Catherine M. , Somerfield, Mark R. , Lee, Janie M. , Hieken, Tina J. , Magnuson, Allison , Rao, Ruta , Chew, Helen K., Chia, Stephen , Harvey, Brittany , Landsberger, Ellen , Mwanzi, Sitna , Parsons, Heather A. , Patt, DA , Sung, Hyuna , Rao, Ruta , Chia, Stephen K L , Harvey, Brittany E , Lim, Bora , Mwanzi, Sitna Ali , Parsons, Heather A , Sukumar, Jasmine S , Sung, Hyuna , Werutsky, Gustavo , Lustberg, Maryam , Hieken, Tina J , Alfano, Catherine M , Chew, Helen K. , Lim, Bora , Lustberg, Maryam B.

Mayo Clinic

Journal of Clinical Oncology | July 16, 2026 | Volume: 44 | Issue: 30 | Pages: 2953-2971

10.1200/jco-26-01700 | PMID 42462191 Get It

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the https://www.asco.org/practice-patients/guidelines/guideline-methodology . ASCO Guidelines follow the https://www.asco.org/about-asco/legal/conflict-interest-coi . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more . PURPOSE To offer clinicians recommendations concerning breast cancer follow-up and surveillance after primary treatment. METHODS ASCO convened an Expert Panel to develop recommendations based on a systematic review and a formal consensus process. RESULTS One randomized controlled trial (RCT) was identified and formed the evidentiary basis for the surveillance mammography guideline recommendation. No RCTs were identified that evaluated different follow-up approaches by risk of relapse in patients treated for early-stage breast cancer. Given the dearth of evidence identified in the systematic review of the literature, formal modified Delphi consensus-based recommendations were generated. RECOMMENDATIONS The guideline offers recommendations on the role of a risk-based approach to the frequency and intensity of follow-up among patients with breast cancer in the adjuvant setting. Regular history, physical examination, and mammography are recommended for breast cancer follow-up. Either virtual or in-person visits can be offered. Certain patients at a high risk of cancer recurrence warrant closer surveillance, such as those patients with locally advanced disease or residual disease following neoadjuvant chemotherapy. Recommendations on the use of blood-based biomarkers and supplemental imaging are provided. Guideline recommendations will be updated once additional evidence-based tools become available to better individualize surveillance. Additional information is available at www.ascopubs.org/topics/asco-guidelines/breast-cancer .
ETHAN: A phase II study comparing different endocrine therapies for male breast cancer.
Leone, José Pablo , Ruddy, Kathryn J. , Rashid, Naim U. , Ortiz-Perez, Tamara, Abdou, Yara, Sharpe, Jessica Mezzanotte, McAuliffe, Priscilla F., Park, Ben Ho, Quintana, Liza M., Schnitt, Stuart J., Krop, Ian E. , Thompson, Alastair M. , Sukumar, Jasmine S , Giordano, Sharon H. , Gupta, Gaorav P , Hilsenbeck, Susan Galloway , Walsh, Elaine M. , Makhlin, Igor , Abdou, Yara, Sharpe, Jessica Mezzanotte, McAuliffe, Priscilla F., Park, Ben Ho, Quintana, Liza M., Schnitt, Stuart J., Spanheimer, Philip M. , Wolff, Antonio C.

Mayo Clinic

Journal of Clinical Oncology | May 29, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS632-TPS632

10.1200/jco.2024.42.16_suppl.tps632 Get It

TPS632 Background: Male breast cancer is a rare disease, and most cases are hormone receptor-positive (HR+). Due to a lack of clinical trials, male breast cancer has historically been treated based on data extrapolated from women. However, there are substantial knowledge gaps in the comparative efficacy, safety, and patient-reported outcomes of endocrine therapies for male breast cancer. While tamoxifen is the current standard of care, additional data are warranted for aromatase inhibitors (AI), gonadal suppression, and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. Methods: This is an open-label, multicenter, randomized, phase II trial designed to evaluate different endocrine therapies in men with HR+ and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. A total of 60 men will be enrolled across nine (9) sites within the Translational Breast Cancer Research Consortium (TBCRC). Key eligibility criteria include male sex and stage I, II, or III HR+/HER2- breast cancer before surgical resection of the primary tumor and axillary nodes. Key exclusion criteria include prior anti-cancer therapy for the current breast cancer or any other malignancy within the past 12 months, and inflammatory breast cancer. The trial has two phases. The first phase is a window of opportunity component in which newly diagnosed men are randomized 1:1:1 to either tamoxifen (Arm A), anastrozole (Arm B), or anastrozole plus degarelix (Arm C) given for three weeks. The primary endpoint for the window phase is Ki-67 reduction from the baseline diagnostic biopsy to the research biopsy at the end of the window phase. The second phase consists of neoadjuvant treatment, in which the tamoxifen group is randomized 1:1 to tamoxifen (Arm D) versus tamoxifen plus abemaciclib (Arm E), and the anastrozole alone (Arm B) and anastrozole plus degarelix (Arm C) groups are merged and then randomized 1:1 to anastrozole plus degarelix (Arm F) versus anastrozole plus degarelix plus abemaciclib (Arm G). The duration of the neoadjuvant phase is four (4) months, and the primary endpoint of this phase is residual cancer burden (RCB) index at time of surgery. The trial is powered for the RCB endpoint in a 2 x 2 factorial design to detect a 0.6 unit decrease in RCB index with 80% power and alpha=10%. For the Ki-67 endpoint, we assume an approximately 50% reduction in Arms A and B; Arm C will be of interest if it leads to ≥80% reduction in Ki-67. Secondary endpoints include: estradiol and testosterone levels at baseline, end of window, and during neoadjuvant phase; preoperative endocrine prognostic index (PEPI) score at surgery; adverse events; and patient-reported outcomes (including quality of life). Tumor tissue will be collected for correlative analyses. The study opened to enrollment at Dana-Farber in October 2023, and additional sites will open in 2024. Clinical trial information: NCT05501704 .
Metastatic non-small cell lung cancer (NSCLC) and brain edema: a topographical and clinicopathological investigation utilizing deep learning-based artificial intelligence (DLBAI)
Yun, Jonathan , Kurker, Kristina P. , Kumar, Jeyan S. , Sutherland, Grant , Farzad, Faraz, Sukumar, Rohit , Yener, Ulaş, Patel, Sohil H. , Schiff, David , Lopes, Beatriz, Mut, Melike , Maragkos, Georgios Α. , Feng, Xue

Mayo Clinic

No container title available | January 19, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3851661/v1 Get It

Abstract Tumor-associated vasogenic brain edema is a well-known contributor of morbidity and mortality in patients with metastatic disease to the brain. It is widely accepted that brain metastases (BM) is associated with extensive edema and can cause increased symptomatology such as pain, neurologic deficit, and elevated intracranial pressure depending on extent and location. We present a proof-of-concept retrospective analysis utilizing DLBAI to segment and detect radiological and topographical patterns of peritumoral edema and assess for clinicopathological correlates in 84 patients with NSCLC and BM who underwent surgical resection and were not previously on steroids. We found that overall, tumors in all locations demonstrated a mean 10:1 edema to tumor ratio (ETR) and an occipital tumor location was associated with a significantly elevated ETR. Within our cohort there were no other factors that were significantly associated with ETR. This study demonstrates a proof-of-concept that DLBAI is an efficient and accurate method of radiographic analysis that can be applied to detect and potentially predict clinicopathological data and prognostic determinants. Clinically, we demonstrate that NSCLC is associated with significant peritumoral edema and that topographical factors may be associated with increased extent of edema.
Pregnancy and Immune Mediated Thrombotic Thrombocytopenic Purpura (iTTP); A Descriptive Analysis from the U.S. Thrombotic Microangiopathy (USTMA) Registry
Masias, Camila , Akwaa, Frank, Gangaraju, Radhika , Antun, Ana G., Sridharan, Meera , Burwick, Richard M. , Java, Anuja , Mazepa, Marshall , Sukumar, Senthil

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 4009-4009

10.1182/blood-2023-186167 Get It

Background: Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is defined by thrombocytopenia and microangiopathic hemolytic anemia without an alternative explanation, confirmed by severely deficient ADAMTS13 (A disintegrin and metalloproteinase with thrombospondin type 1 motifs, member 13) to <10%. It is caused by autoantibodies against the ADAMTS13 protease. Pregnancy can precipitate iTTP, but the diagnosis and treatment are challenging, since it is often difficult to differentiate from other TMAs associated with pregnancy The aim of this study was to describe the clinical presentation, treatment, and outcomes of pregnancy related iTTP. Methods: Data was obtained from the USTMA retrospective database, including 15 large USTMA referral centers. Patients were identified based on the diagnosis of iTTP provoked by pregnancy between 9/6/1990 and 6/18/2018. The study cohort included participants with a clinical diagnosis of iTTP, confirmed by ADAMTS13 activity <10% who had a pregnancy or recent delivery within 30 days of presenting with iTTP. For participants diagnosed before the ADAMTS13 assay was developed (2006), the iTTP diagnosis was based on the clinical course and absence of alternative causes. iTTP exacerbation was defined as clinical disease recurrence within 30 days of PLEX (plasma exchange) discontinuation, and clinical relapse was defined as disease recurrence after 30 days of last PLEX. Maternal and fetal outcomes were additionally collected from 7/15 sites. Results: 42 patients had 55 iTTP episodes provoked by pregnancy. Median age for patients was 29. Sixteen (38.1%) were white, 20 (47.6%) were black. The most common presenting symptoms were headache and fatigue in 11/55 (20%) episodes. Thirty nine (70.9%) episodes had a platelet count <30 x10 9/L, and 46 (83.6%) had laboratory findings concerning for hemolysis as evidenced by elevated lactate dehydrogenase (LDH) and/or schistocytes present on peripheral smear. Only 5 (9%) episodes presented with a creatinine >2 mg/dL. ADAMTS13 activity was documented in 33 (60%) episodes and was <10% in 30 (90.9%) (Table 1). Treatment with PLEX was described in 30 (54.5%) episodes with a median duration of 6 days (2-26 days). Further immunosuppression included prednisone in 38 (69.1%) episodes and rituximab in 11 (20%), of which 7 (63.6%) had no future exacerbations or relapses during the study period.Seventeen (40.5%) patients had a prior diagnosis of iTTP. There were 10 exacerbations in 8 patients (19%), and 34 relapses in 13 (30%) patients after the 55-pregnancy provoked iTTP episodes. Five of those relapses were triggered again by pregnancy. Pregnancy related outcomes were obtained in 16 patients. Twenty five percent (4/16) of patients had a prior history of iTTP; median time of last iTTP to current presentation was 34 months (10-108). Of 16 patients, iTTP occurred with first pregnancy in 8 patients. Of the remaining eight patients, iTTP occurred in the eleventh (n=1), ninth (n=1), sixth (n=1), fifth (n=1), fourth (n=2), and unknown (n=2) pregnancy. Only 13 of 16 patients had further pregnancy specific outcomes available (Table 2). Preeclampsia was noted in 3 patients. Seven and 1 patients, presented with iTTP within 30 days postpartum or after miscarriage, respectively. The remaining patients (n=5) developed iTTP during the antepartum period. Of these, 2 pregnancies were terminated due to iTTP (second trimester and third trimester). One of the three remaining pregnancies resulted in fetal demise at 24 weeks. The latter two patients delivered healthy infants. There were no maternal deaths in our cohort. Conclusions: This is first multicenter descriptive analysis of pregnancy related iTTP from the USTMA registry. The clinical presentation of this cohort is consistent with iTTP triggered by other causes, and the low rate of acute kidney injury is helpful in identifying iTTP from other TMAs in pregnancy. We observed that pregnancy is a risk not only for acute episodes of iTTP in first pregnancy, but also in subsequent pregnancies and in the relapse setting of those with previous diagnosis of iTTP. While there was a 20% and 30% exacerbation and relapse rate respectively, maternal mortality was not observed. Rituximab did not affect maternal mortality. Fetal mortality was affected by iTTP in the antepartum period. These findings will serve as bases of prospective USTMA study for standardize management of this population.
Abstract P4-02-09: Evaluation of the Automated Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC-005 Prospective Trial
Cope, Leslie , Fackler, Mary Jo , Forero-Torres, Andres , Nanda, Rita , Storniolo, Anna Maria , Tulač, Suzana, Wu, Natalie C. , Marla, Sudhakar , Venkatesan, Neesha R., Visvanathan, Kala , Considine, Michael , Carey, Lisa A. , Ingle, James N. , Lin, Nancy U. , Tulac, Suzana , Venkatesan, Neesha , Wolff, Antonio C. , Sukumar, Saraswati

Mayo Clinic

Cancer Research | March 2, 2023 | Volume: 83 | Issue: 5_Supplement | Pages: P4-02-09-P4-02-09

10.1158/1538-7445.sabcs22-p4-02-09 Get It

Abstract Purpose: We previously demonstrated that high levels of circulating methylated DNA are associated with subsequent disease progression in women with metastatic breast cancer (MBC). In this study, we validated the clinical utility of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) prototype assay using the GeneXpert® cartridge system for early assessment of disease progression in MBC. Study Design: The 9-marker, LBx-BCM prototype assay was evaluated in TBCRC-005, a prospective biomarker study, using plasma collected at baseline, week 4 and week 8 from 144 MBC patients. Results: At week 4 MBC patients with high cumulative methylation (CM) had a significantly shorter median PFS (2.88 months v 6.60 months, p = 0.001) and OS (14.52 months v 22.44 months, p=0.005) compared to those with low CM. In a multivariable model, high versus low CM was also associated with shorter PFS (HR = 1.90, 95%CI 1.20-3.01; p =0.006). Change in CM from baseline to week 4 (OR = 4.60, 95%CI 1.77, 11.93; p = 0.002) and high levels of CM at week 4 (OR = 2.78, 95%CI 1.29, 5.99; p = 0.009) were associated with progressive disease at the time of first restaging. A robust risk model (AUC = 0.733) based on week 4 circulating CM levels was developed to predict disease progression as early as 3 months after initiating a new treatment. Conclusion: The easy to perform and automated LBx-BCM prototype assay is a promising clinical tool for detecting disease progression early after initiating treatment in women with MBC. Further validation in larger clinical datasets is needed. Citation Format: Kala Visvanathan, Leslie Cope, Mary Jo Fackler, Michael Considine, Lisa Carey, Andres Forero-Torres, James N. Ingle, Nancy U. Lin, Rita Nanda, Anna Maria Storniolo, Suzana Tulac, Natalie C. Wu, Sudhakar Marla, Neesha R. Venkatesan, Antonio C. Wolff, Saraswati Sukumar. Evaluation of the Automated Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC-005 Prospective Trial [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P4-02-09.
Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Visvanathan, Kala , Cope, Leslie , Fackler, Mary Jo , Considine, Michael , Sokoll, Lori J. , Carey, Lisa A. , Forero-Torres, Andres , Ingle, James N. , Lin, Nancy U. , Nanda, Rita , Storniolo, Anna Maria , Tulac, Suzana , Venkatesan, Neesha , Wu, Natalie C. , Marla, Sudhakar , Campbell, Scott , Bates, Michael , Umbricht, Christopher B. , Ingle, J , Sokoll, Lori , Wolff, Antonio C , Sukumar, Saraswati , Carey, Lisa A , Visvanathan, Kala , Lin, Nancy U , Wolff, Antonio C.

Mayo Clinic

Clinical Cancer Research | December 19, 2022 | Volume: 29 | Issue: 4 | Pages: 784-790

10.1158/1078-0432.ccr-22-2128 | PMID 36534524 Get It

Abstract Purpose: We previously demonstrated that high levels of circulating methylated DNA are associated with subsequent disease progression in women with metastatic breast cancer (MBC). In this study, we evaluated the clinical utility of a novel liquid biopsy-breast cancer methylation (LBx-BCM) prototype assay using the GeneXpert cartridge system for early assessment of disease progression in MBC. Experimental Design: The 9-marker LBx-BCM prototype assay was evaluated in TBCRC 005, a prospective biomarker study, using plasma collected at baseline, week 4, and week 8 from 144 patients with MBC. Results: At week 4, patients with MBC with high cumulative methylation (CM) had a significantly shorter median PFS (2.88 months vs. 6.60 months, P = 0.001) and OS (14.52 months vs. 22.44 months, P = 0.005) compared with those with low CM. In a multivariable model, high versus low CM was also associated with shorter PFS (HR, 1.90; 95% CI, 1.20–3.01; P = 0.006). Change in CM from baseline to week 4 (OR, 4.60; 95% CI, 1.77–11.93; P = 0.002) and high levels of CM at week 4 (OR, 2.78; 95% CI, 1.29–5.99; P = 0.009) were associated with progressive disease at the time of first restaging. A robust risk model based on week 4 circulating CM levels was developed to predict disease progression as early as 3 months after initiating a new treatment. Conclusions: The automated LBx-BCM prototype assay is a promising clinical tool for detecting disease progression a month after initiating treatment in women with MBC undergoing routine care. The next step is to validate its clinical utility for specific treatments.
Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis
Johnson, Janel O., Chia, Ruth , Miller, Danny E. , Kumaran, Ravindran, Abramzon, Yevgeniya, Alahmady, Nada F. , Topp, Simon , Gibbs, J. Raphael , Cookson, Mark , Sabir, Marya S. , Dalgard, Clifton L. , Troakes, Claire , Jones, Ashley R., Shatunov, Aleksey , Iacoangeli, Alfredo , Khleifat, Ahmad Al , Ticozzi, Nicola , Gellera, Cinzia , Blair, Ian P. , Dobson‐Stone, Carol , Bonkowski, Emily , Palvadeau, Robin , Tienari, Pentti J. , Morrison, Karen , Shaw, Pamela J. , Brown, Robert H., Calvo, Andrea, Al-Saif, Hind, Leigh, Fawn, Chang, Irene J. , Perlman, Seth J. , Scott, Anna I. , Başak, A. Nazlı , Landers, John E. , Crawford, Thomas O. , Smith, Bradley , Traynor, Bryan J. , Gkazi, Athina Soragia, Kenna, Kevin P., Keagle, Pamela, Tiloca, Cinzia , Vance, Caroline , King, Andrew , Pensato, Viviana , Castellotti, Barbara , Baas, Frank , Asbroek, Anneloor L.M.A. ten , McKenna‐Yasek, Diane, McLaughlin, Russell L. , Polak, Meraida , Asress, Seneshaw, Stević, Zorica, D’Alfonso, Sandra , Mazzini, Letizia, Bo, Roberto Del, Gagliardi, Stella , Querin, Giorgia, Bertolin, Cinzia , Rademakers, Rosa, Blitterswijk, Marka van , Lauria, Giuseppe, Corrado, Lucia , Sorarú, Gianni , Williams, Kelly L. , Leblond-Manry, Claire, Hardiman, Orla , Berg, Leonard H. van den, Pall, Hardev, Taroni, Franco , Wu, Zheyang , Glass, Jonathan D., Ratti, Antonia, Adeleye, Adelani, Alba, Camille , Viollet, Coralie , Bačíková, Dagmar, Hupalo, Daniel N., Pollard, Harvey B. , Martinez, Elisa McGrath, Ahmed, Sarah , Arepalli, Sampath, Baloh, Robert H. , Bowser, Robert , Campbell, Roy H. , Camu, William, Cooper‐Knock, Johnathan , Ding, Jinhui, Drory, Vivian E., Dunckley, Travis , Eicher, John D., England, Bryce, Faghri, Faraz , Feldman, Eva, Floeter, Mary Kay, Fratta, Pietro , Geiger, Joshua T. , Gibson, Summer, Hardy, John , Harms, Matthew , Heiman‐Patterson, Terry , Hernandez, Dena G., Jansson, Lilja, Kowall, Neil W. , Laaksovirta, Hannu , Landi, Francesco , Ber, Isabelle Le , Lumbroso, Serge , MacGowan, Daniel J., Maragakis, Nicholas J., Mouzat, Kévin , Murphy, Natalie A., Myllykangas, Liisa , Nalls, Mike A., Orrell, Richard W., Ostrow, Lyle W., Pickering‐Brown, Stuart , Pioro, Erik P., Pletniková, Olga , Ravits, John , Rivera, Alberto , Robberecht, Wim, Rogaeva, Ekaterina, Rollinson, Sara, Rothstein, Jeffrey D., Scholz, Sonja W. , Sendtner, Michael , Sidle, Katie, Singleton, Andrew, Smith, Nathan, Stone, David J. , Troncoso, Juan C., Valori, Miko , Damme, Philip Van , Deerlin, Vivianna M Van, Bosch, Ludo Van Den , Zinman, Lorne, Landers, John E., Chiò, Adriano, Angelocola, Stefania, Ausiello, Francesco P., Barberis, Marco, Bartolomei, Ilaria, Battistini, Stefania, Bisogni, Giulia , Borghero, Giuseppe , Brunetti, Maura, Canale, Fabrizio , Canosa, Antonio, Cantisani, Teresa A., Cardinali, Patrizio, Casale, Federico , Colletti, Tiziana , Conforti, F. L. , Conte, Amelia , Conti, Elisa, Corbo, Massimo , Cuccu, Stefania, D’Errico, Eustachio , Marco, Giovanni De , Dubbioso, Raffaele, Ferrarese, Carlo , Ferraro, Pilar M. , Floris, Gianluca , Fuda, Giuseppe, Gallone, Salvatore , Gianferrari, Giulia , Giannini, Fabio, Grassano, Maurizio, Greco, Lucia Catherine , Iazzolino, Barbara, Introna, Alessandro , Logroscino, Giancarlo , Logullo, Francesco, Lunetta, Christian , Mandich, Paola , Mandrioli, Jessica , Manera, Umberto , Manganelli, Fiore, Martinelli, Ilaria , Moglia, Cristina, Mosca, Lorena, Murru, Maria Rita, Origone, Paola , Petrelli, Cristina, Pozzi, Susanna, Pugliatti, Maura , Ricci, Claudia , Riolo, Giulia , Russo, Massimo, Salamone, Paolina, Salivetto, Marco, Salvi, Fabrizio, Santarelli, Marialuisa, Sbaiz, Luca, Sideri, Riccardo , Simonini, Cecilia , Tanel, Raffaella , Tedeschi, Gioacchino, Ticca, Anna, Torriello, Antonella, Tranquilli, Stefania, Tremolizzo, Lucio , Vasta, Rosario , Vacchiano, Veria, Volanti, Paolo , Zollino, Marcella , Lauria, Giuseppe , Ratti, Antonia , Ostrow, Lyle W. , Fratta, Pietro , Chia, Ruth , Logroscino, Giancarlo , van Blitterswijk, Marka , Scholz, Sonja W , Van Den Bosch, Ludo , Van Damme, Philip , Hardy, John , Fratta, Pietro , Fratta, Pietro , Troakes, Claire , Hardiman, Orla , Dalgard, Clifton L , Myllykangas, Liisa , Li, Rachel , Renton, Alan , Jones, Ashley R., Silani, Vincenzo , Kwok, John B. , Al‐Chalabi, Ammar , Calvo, Andrea , Mora, Gabriele , Gotkine, Marc , Glass, Ian A. , Shaw, Christopher E. , Chiò, Adriano , Fallini, Claudia , Gkazi, Soragia Athina , Scotter, Emma L. , Kenna, Kevin Patrick , Keagle, Pamela , Colombrita, Claudia , Asress, Seneshaw, Esteban‐Pérez, Jesús , Mazzini, Letizia , Comi, Giacomo P. , Ceroni, Mauro , Rheenen, Wouter van , Rademakers, Rosa , Duga, Stefano , Corti, Stefania Paola , Cereda, Cristina , Nicholson, Garth A. , Rouleau, Guy Armand , Veldink, Jan H. , Berg, Leonard H. van den , Turner, Martin R. , Talbot, Kevin , García‐Redondo, Alberto , Adeleye, Adelani, Soltis, Anthony R. , Sukumar, Gauthaman , Wilkerson, Matthew D. , Brady, Christopher B. , Brice, Alexis , Broach, James R , Campbell, Roy H., Ding, Jinhui , Drepper, Carsten , Gerhard, Glenn S. , Harms, Matthew B. , Hernandez, Dena G., Kirby, Janine , Landeck, Natalie , Maragakis, Nicholas J. , Pamphlett, Roger , Pliner, Hannah A. , Pulst, Stefan M. , Rothstein, Jeffrey D. , Simmons, Zachary , Singleton, Andrew , Smith, Nathan, Troncoso, Juan C. , Deerlin, Vivianna M. Van , Zinman, Lorne , Ausiello, Francesco Pio, Barberis, Marco , Battistini, Stefania , Bersano, Enrica , Brunetti, Maura , Cabona, Corrado , Canosa, Antonio , Capasso, Margherita , Caponnetto, Claudia , Carrera, Paola , Bella, Eleonora Dalla , Dubbioso, Raffaele , Filippi, Massimo , Fini, Nicola , Grassano, Maurizio , Iazzolino, Barbara, Bella, Vincenzo La , Lattante, Serena , Liguori, Rocco , Manganelli, Fiore , Marangi, Giuseppe , Marinou, Kalliopi , Marrosu, Maria Giovanna , Messina, Sonia , Moglia, Cristina , Mosca, Lorena, Passaniti, Carla , Petrucci, Antonio , Quattrini, Angelo , Riva, Nilo , Russo, Massimo, Sabatelli, Mario , Salamone, Paolina , Simone, Isabella Laura , Spataro, Rossella , Tedeschi, Gioacchino , Trojsi, Francesca , Vacchiano, Veria , Vita, Giuseppe , Zucchi, Elisabetta

Mayo Clinic

JAMA Neurology | August 30, 2021 | Volume: 78 | Issue: 10 | Pages: 1236

10.1001/jamaneurol.2021.2598 | PMID 34459874 Get It

DNA methylation in serum as an independent marker of outcome and treatment response in TBCRC 005: A prospective study in metastatic breast cancer (MBC) patients.
Fackler, Mary Jo , Lopez‐Bujanda, Zoila A. , Jeter, Stacie C., Sokoll, Lori J. , Cope, Leslie , Umbricht, Christopher B. , Euhus, David , Carpenter, John T., Storniolo, Anna Maria , Nanda, Rita , Lopez-Bujanda, Zoila A , Visvanathan, Kala , Zhang, Zhe , Lin, Nancy U. , Carey, Lisa A. , Ingle, James N. , Sukumar, Saraswati , Wolff, Antonio C.

Mayo Clinic

Journal of Clinical Oncology | March 8, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 518-518

10.1200/jco.2015.33.15_suppl.518 Get It

Abstract P1-09-15: Tumor and serum DNA methylation in women receiving preoperative chemotherapy (PST) with or without vorinostat in primary operable HER2-negative breast cancer in TBCRC008
Connolly, RM, Fackler, MJ, Zhang, Z , Xc, Zhou, Goetz, MP, Boughey, JC , Walsh, Bridget A. , Carpenter, John T., Storniolo, AM, Barielson, E, Walsh, B, Watkins, S, Sukumar, Saraswati , Stearns, Vered

Mayo Clinic

Cancer Research | March 1, 2017 | Volume: 77 | Issue: 4_Supplement | Pages: P1-09-15-P1-09-15

10.1158/1538-7445.sabcs16-p1-09-15 Get It

Abstract Background: DNA methylation is a promising prognostic and predictive biomarker of response to treatment in advanced breast cancer (Fackler MJ. Can Res 2014). We evaluated whether baseline and change in tissue and serum methylation would predict pathological complete response (pCR) in patients with HER2-negative early breast cancer treated with PST. Methods: TBCRC008 was a multicenter placebo-controlled trial that investigated pCR (no invasive cancer in breast/axilla) following 12 weeks of preoperative carboplatin and albumin-bound paclitaxel with or without the histone deacetylase (HDAC) inhibitor vorinostat in 62 patients with HER2-negative breast cancer. We performed an exploratory planned biomarker study correlating baseline and change (D15) in tumor tissue and serum methylation with pCR. Methylation was measured using cumulative methylation index (CMI) in quantitative multiplexed methylation-specific polymerase chain reaction (QM-MSP) assays; cMethDNA assay for serum (Fackler MJ. Can Res 2014) and QM-MSP for tissue (Fackler MJ. Can Res 2004). The analysis population included all patients with available methylation and pCR data. Association between CMI level (log transformed baseline, D15, change) and pCR was evaluated using univariate as well as multivariable logistic regression models controlling for treatment arm and estrogen receptor (ER) status. Additional subgroup analyses assessed association of CMI level with pCR stratified by ER status and treatment arms, respectively. Spearman's correlation coefficient was performed to evaluate the correlation between tissue and serum CMI. Results: pCR data were available for 61 of 62 patients. One patient with unknown response was treated as a non-responder. The pCR rate was similar in both arms (vorinostat 25.8%, placebo 29%). Both tissue and serum CMI data were available in 55 (baseline), 50 (D15) and 46 (change) patients. Elevated serum methylation based on a predefined threshold (6.9 units) was identified in 23/59 (39%) patients. In univariate analysis, one log unit increase in tissue CMI levels at D15 was associated with a 40% lower chance of obtaining a pCR (odds ratio, OR=0.60, 95% CI 0.37-0.97; p=0.037). The multivariable analysis did not show a statistically significant association of tissue or serum CMI with pCR, although a similar trend in magnitude towards association with pCR was observed for D15 and change in tumor tissue CMI (OR 0.67 and 0.57, p=0.129 and 0.147 respectively). Subgroup analyses suggested a significant association between tissue CMI levels at D15 and pCR in the group treated with vorinostat [tissue OR: 0.44 (0.20, 0.93), p=0.03; serum OR 0.37 (0.13, 1.07), p=0.07] but not in the placebo group. No significant correlation was observed between tissue and serum CMI. Conclusion: This is the first study to evaluate the predictive role of tissue and serum methylation (CMI) in patients with early breast cancer treated with PST ± an HDAC inhibitor. Methylation was detected more frequently in tissue than serum. Tissue CMI levels at D15 may predict poor response to this regimen. Further evaluation of the predictive role of methylation in early breast cancer is warranted. Citation Format: Connolly RM, Fackler MJ, Zhang Z, Zhou XC, Goetz MP, Boughey JC, Walsh B, Carpenter J, Storniolo AM, Watkins S, Barielson E, Sukumar S, Stearns V. Tumor and serum DNA methylation in women receiving preoperative chemotherapy (PST) with or without vorinostat in primary operable HER2-negative breast cancer in TBCRC008 [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-09-15.
Abstract P2-06-01: cMethDNA is a quantitative circulating methylated DNA assay for detection of metastatic breast cancer and for monitoring response to therapy
Fackler, MJ, Bujanda, ZL, Umbricht, Christopher B. , Teo, WW, Zhang, Z , Jeter, S. C., Argani, P., Wang, C, Ingle, JN, Boughey, JC , McGuire, Kandace P. , King, TA, Carey, LA, Cope, L. A., Sukumar, S, Lopez‐Bujanda, Zoila A. , Visvanathan, Kala , Wolff, Antonio C. , Sukumar, Saraswati , Lopez-Bujanda, Zoila A

Mayo Clinic

Cancer Research | August 14, 2014 | Volume: 73 | Issue: 24_Supplement | Pages: P2-06-01-P2-06-01

10.1158/0008-5472.sabcs13-p2-06-01 Get It

Abstract Background- The ability to consistently detect cell-free tumor-specific DNA in peripheral blood of patients with metastatic breast cancer provides the opportunity to detect changes in tumor burden and to monitor response to treatment. Studies of cell-free DNA in the peripheral blood of breast cancer patients suggest that methylated DNA markers in serum or plasma could be used for detection of advanced disease, monitoring of therapeutic response, and for early detection of disease recurrence. Methods- A genome-wide serum DNA methylome array (Illumina HumanMethylation27 BeadChip) analysis was conducted on cell-free circulating DNA in serum from women with stage IV recurrent breast cancer, and 232 key CpG loci were identified. Methylation for this panel of 10 gene loci was evaluated using our newly developed cMethDNA assay to detect miniscule amounts of methylated DNA in Training and Test sets of sera from a total of 112 women (n = 55 normal, n = 57 metastatic breast cancer). The clinical sensitivity and specificity of the assay, along with technical reproducibility, was determined. To evaluate the concordance of DNA methylation patterns, the 10 gene panel was tested on 22 DNA sets of primary tumor, metastases and serum from the same patient. Finally, the ability of cMethDNA to monitor response to therapy was evaluated in 28 patients with metastatic disease. Results- A normal laboratory threshold of 7 cumulative methylation units was set and assay parameters were locked, based on Receiver Operating Characteristic (ROC) analyses of DNA from 300 ul of patient sera in the Training set (normal, n = 28; cancer, n = 24; 92% sensitivity, 96% specificity, and AUC = 0.950). Evaluation of the Test set of patient sera (normal, n = 27; cancer n = 33) resulted in detection of metastatic breast cancer with 91% sensitivity, 100% specificity, and AUC = 0.994 (0.984-1.005, p<0.0001). Reproducibility of the cMethDNA assay increased with copy number; with the highest variation at 50 copies (CV = 29.1%) and the lowest at 3,200 copies (CV = 2.5%) of methylated DNA. The test was shown to be operator independent (ICC = 0.99). Evaluation of concordance between primary and disseminated tumor methylation showed that the methylation pattern from any given individual is highly conserved between serum, primary tissue and their metastases, and poorly conserved between different individuals. cMethDNA analysis of 28 patients before and after initiation of therapy showed a decrease in cumulative methylation in women with stable/responsive disease and a correlation with disease progression free survival (p<0.0001). Conclusion- Together, our data suggest that the cMethDNA test 1) can detect tumor DNA shed into blood, 2) reflect the methylation alterations typical of the primary tumor and its metastatic lesions, and 3) reflect response to treatment after chemotherapy. Next, we will test the clinical utility of cMethDNA in independent clinical trial sample sets where it's complementary and independent roles will be examined against CA15.3 and CTC assays. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-06-01.